Catalyst Wire Dossier Catalyst Wire Dossier
FDA label_change · 2020-09-29

FDA Approved: LATISSE — Supplemental Application (Allergan, Inc.)

View source ↗

Summary

FDA approved a supplemental application for LATISSE (bimatoprost) by Allergan, updating the labeling to reflect its approved use for eyelash hypotrichosis (inad…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • LATISSE (BIMATOPROST)

Snippet

SUPPL AP for LATISSE (BIMATOPROST)